Notice on the expected shortage of Propranolol Sandoz 40 mg tablets (propranolol)
Sandoz d.o.o., the marketing authorisation holder for Propranolol Sandoz 40 mg tablets (propranolol) has notified the agency for Medicinal Products and Medical Devices (HALMED) on the expected shortage of this medicinal product on the Croatian market. The shortage is due to manufacturing or purchase problems of the active substance.
The normalisation of the supply chain is expected by mid of March 2015.
Other medicinal products from the same therapeutic group containing other active substances are authorised and available on the Croatian market. All patients who remain without therapy should consult their doctor about the continuation of the therapy. In the case that the therapy with authorised medicinal products from the same therapeutic group is not applicable, HALMED will for urgent treatments, on wholesaler’s request approve enter/import of medicinal products not having marketing authorisation in the Republic of Croatia, but containing the same active substance as the medicinal product affected by the shortage.